Meza-Oviedo D, Meza-Oviedo Y, Rosales-Del Real O, Porras-Méndez CMV, Morones-Esquivel I, Salgado-Muñoz TG, Castro-D’Franchis LJ, Reyes-Jiménez AE, Terán-González JÓ, Labastida-Bautista MÁ, Alba-Rangel L, Ríos-Villalba P, Victoria-Moreno A

Language: Spanish
References: 9
Page: 241-247
PDF size: 275.74 Kb.

ABSTRACT

Background: The increased infections due to multiresistant gramnegative bacteria and loss therapeutic resources have led to the use of colistimethate sodium in clinical practice, originally abandoned due to its high nephrotoxicity. The mechanisms of renal toxicity are not well understood but are believed to be dose-dependent.
Objective: To establish the relationship between the cumulative dose of colistimethate and nephrotoxicity.
Material and method: A retrospective cohort of four years including 24 patients who received intravenous colistimethate for more than 72 hours in a hospital in Mexico City to determine the correlation between cumulative dose of colistimethate and nephrotoxicity.
Results: Eleven patients developed nephrotoxicity. Mean cumulative dose in patients with nephrotoxicity was 2,400 mg-2,700 mg vs those who did not develop (p=0.18), the dosege was of 4.53 vs 3.61 mg/kg/day, p=0.67. Prior diagnosis of diabetes mellitus was an inddependent predictor for developing renal toxicity.
Conclusions: In this retrospective cohort study, the incidence of nephrotoxicity was demonstrated in 11 of 24 patients; however, there is no significant relationship betwen cumulative dose or dose-mg/kg/day and nephrotoxicity. The most significantwith previous diagnosis risk factor for nephrotoxicity found in patients with previous diagnosis of diabetes mellitus.

REFERENCES

1. Gül R, Yilmaz ATB, Ayse But, Sümeyye Yildiz, et al. Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug resistant gram-negative pathogens. J Infec Chemother 2013;19:57-62.

2. Pogue JL, Marchaim D, Yee V, et al. Incidence of and risk factors for colistin-associated nephrotoxiciity in a large academic health system. Clin Infec Dis 2011;53:879-84.

3. GauthierTP, Wolowich WR, Reddy A, Cano E, et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012;56:2392-2396.

4. Rocco M, Alessandri E, Venditti M, Laderchi A, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 2013;17:174.

5. DeRyke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503-4505.

6. Kwon JA, Lee JE, Huh W, Peck KR, et al. Predictors of acute kindey injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010;35:473-477.

7. Hartzell JD, Ake J, Howard R, Olson S, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infec Dis 2009;48:1724-1728.

8. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.clin Infec Dis 2013;57:1300-1303.

9. Ghlissi Z, Sila A, Mnif H, Zeghalk, et al. Evaluation of efficacy of natural astaxanthin andvitamin E in prevention of colistin-induced nephrotoxicity in the rat model. Environ Toxicol Pharmacol 2014;37:960-966.